Bridgeway Capital Management’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
Other funds holding PTCT
Bridgeway Capital Management's PTCT Position: Q3 2026 in Review
Bridgeway Capital Management sold out of PTC Therapeutics (PTCT) in Q3 2026, closing a stake of 22,000 shares — an estimated $1.79M sold.
Bridgeway Capital Management first reported a position in PTCT in Q1 2016 and held it in 5 quarters. The position peaked at $2.57M in Q3 2025. 360 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.
- Bridgeway Capital Management reported no remaining PTC Therapeutics position as of Q3 2026 after selling out during the quarter.
- Bridgeway Capital Management sold 22,000 PTC Therapeutics shares in Q3 2026, an estimated $1.79M.
- Bridgeway Capital Management first reported a position in PTC Therapeutics in Q1 2016 and held it in 5 quarters.
- Bridgeway Capital Management's PTC Therapeutics position peaked at $2.57M in Q3 2025.
- 360 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.
Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.